Fred Brown

1993 and free circulation of vaccines within the E.E.C.

Vyprodáno

Fred Brown 1993 and free circulation of vaccines within the E.E.C.

4,3

Proceedings of a symposium / International Symposium on Standardization of the Immunopharmacology of Natural and Synthetic Immunomodulators

Vyprodáno

Fred Brown Proceedings of a symposium / International Symposium on Standardization of the Immunopharmacology of Natural and Synthetic Immunomodulators

4,3

International Symposium on Continuous Cell Lines - an International Workshop on Current Issues

Vyprodáno

Fred Brown International Symposium on Continuous Cell Lines - an International Workshop on Current Issues

4,3

International Workshop on Poliovirus Attenuation

Vyprodáno

Fred Brown International Workshop on Poliovirus Attenuation

4,3

International Meeting on Transmissible Spongiform Encephalopathies

Vyprodáno

Fred Brown International Meeting on Transmissible Spongiform Encephalopathies

4,3

Virological safety aspects of plasma derivatives

Vyprodáno

Fred Brown Virological safety aspects of plasma derivatives

4,3

Recombinant vectors in vaccine development

Vyprodáno

Fred Brown Recombinant vectors in vaccine development

4,3

Genetic stability and recombinant product consistency

Vyprodáno

Fred Brown Genetic stability and recombinant product consistency

4,3

Replacement, reduction and refinement of animal experiments in the development and control of biological products

Vyprodáno

Fred Brown Replacement, reduction and refinement of animal experiments in the development and control of biological products

4,3

New Approaches to stabilisation of vaccines potency

Vyprodáno

Fred Brown New Approaches to stabilisation of vaccines potency

4,3

Viral safety and evaluation of viral clearance from biopharmaceutical products

Vyprodáno

Fred Brown Viral safety and evaluation of viral clearance from biopharmaceutical products

4,3

Development of specifications for biotechnology pharmaceutical products

Vyprodáno

Fred Brown Development of specifications for biotechnology pharmaceutical products

4,3